The discovery of 2'-spirocyclopropyl-ribocytidine (J. Med. Chem. 2010, 53, 8150-8160) as a potent inhibitor of RNA synthesis by NS5B (IC 50 = 7.3 µM), the RNA polymerase encoded by hepatitis C Virus (HCV), has led to the synthesis and biological evaluation of several carbocyclic versions of 2'-spiropropyl-nucleosides. The cyclopentenol intermediate 7 was successfully constructed via ring-closing metathesis (RCM) from divinyl 6. Spirocyclopropanation of enone 8 was effected by using (2-chloroethyl)-dimethylsulfonium iodide and potassium tert-butoxide to form the desired intermediate 9. The synthesized nucleoside analogues 21-24 were assayed for their ability to inhibit HCV RNA replication in a subgenomic replicon Huh7 cell line. Among them, the cytosine nucleoside analogue 22 exhibited significant anti-HCV activity (EC 50 = 18.2 µM).
Introduction
Hepatitis C virus (HCV) infection is a leading cause of chronic hepatitis, liver cirrhosis and hepatoma carcinoma. However, there is no effective chemotherapy for the treatment of HCV infection except immunotherapy using ribavirin in combination with interferon-α, which leads to a sustained virological response in only about half of the patients treated.
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To date, despite extensive exploration of many novel scaffolds, 3 including carbocyclic derivatives, 4 only two different classes of potent HCV nucleosides have progressed. The first such class of HCV nucleoside inhibitors (NIs) encompasses 2'-modified ribonucleoside derivatives, with 2'-β-C-methyl analogues being particularly important. Among these derivatives, 2'-methylcytidine 5 1 and 2'-methyl-2'-fluorocytidine 6 2 led to the most promising HCV NIs ( Figure 1 ). Through further modification of these derivatives, 2'-deoxy-2'-spirocyclopropylcytidine 7 3 was discovered as a new member of the class of 2'-modified nucleoside derivatives that have HCV inhibiting properties. Compound 3 is a novel potent (EC 50 = 7.3 mM) and selective (CC 50 > 98.4 μM) inhibitor of the HCV NS5B RNA-dependent RNA polymerase, a clinically validated target for HCV treatment.
The 4'-modified ribonucleoside derivatives are the second distinct structural class of HCV NIs. Various substituents at the 4'-position of the sugar are accommodated by NS5B polymerase.
Modeling studies demonstrated the presence of a narrow, relatively hydrophobic 4'-pocket that can accommodate these substitutions, contributing to the observed enhancement in potency. 8 For example, 4'-azidocytidine 9 4 showed excellent anti-HCV activity in the genotype 1b subgenomic replicon system. Natural as well as synthetic carbocyclic nucleosides 10 are well known for their interesting biological activities, including antitumor and antiviral activities against a wide variety of RNA and DNA viruses. Carbocyclic nucleosides are chemically more stable and are subject to the action of the enzymes that cleave the glycosyl linkage in conventional nucleosides.
Result and Discussion
On the basis of these findings that 2'-or 4'-modified ribonucleoside derivatives exhibited excellent anti-HCV activities, we have synthesized novel classes of nucleosides comprising 4'-methyl-2'-spirocyclopropyl carbocyclic nucleoside analogues. The target compounds were prepared as shown in Scheme 1 from the key starting material 5, which was readily synthesized according to our previous published procedure.
11 The aldehyde 5 was treated with vinyl Grignard reagent to form divinyl 6. Without separation of diastereomeric mixture, divinyl 6 was subjected to ring-closing metathesis (RCM) conditions 12 using 2 nd generation Grubbs catalyst to provide the cyclopentenols 7 as a diastereomeric mixture, which was then oxidized to enone derivative 8. Spirocyclopropylation of enone 8 was effected by using (2-chloroethyl)-dimethylsulfonium iodide 13 and potassium tertbutoxide to form two isomers 9 (29%) and 9' (34%), respectively. Reduction of ketone 9 with LiAlH 4 gave two diastereomeric secondary alcohols 10a and 10b. The availability of both stereoisomers in pure condition allowed for confirmation of the stereochemical configuration by NOE methods (Figure 2 ). As expected, NOE enhancements were found between the cis-oriented hydrogens. Upon irradiation of C 6 -CH 3 , a weak NOE pattern was observed at the proximal hydrogen of compound 10a [C 4 -H (0.27%)] versus those of compound 10b [C 4 -H (0.54%)]. The secondary hydroxyl group of 10a was protected as a temporary p-methoxy benzyl ether (PMB) by reaction 14 with PMBCl and NaH in DMF to afford the protected olefin 11. The exomethylene of 11 was treated with ozone in methylene chloride at −78 o C, followed by the decomposition of the ozonide by dimethylsulfide (DMS) to give the ketone 12.
Reaction of reduction reagent (LiAlH 4 ) with cyclopentanone 12 proceeded from the less hindered face of the substrate to provide a mixture of cyclopentanols 13a (59%) and 13b (25%) (Scheme 2). In order to unambiguously confirm the stereochemistry, NOE analysis was performed on 13a and 13b. Upon irradiation of C 7 -H, a strong NOE pattern was observed at the proximal hydrogen of compound 13a [C 4 -H (0.67%)] versus those of compound 13b [C 4 -H (0.42%)] (Figure 3 ). Hydroxyl functional group of 13a was protected with t-butyldimethylsilyl chloride (TBDMSCl) to give compound 14. Oxidative deprotection of the PMB ether moiety of 14 was effected with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) 15 in methylene chloride with a small amount of water to give the alcohol 15, which was transformed into mesylate 16 to prepare for direct S N 2 displacement involving a series of nucleoside bases. 16 The protected spirocarbanucleosides 17-20 were obtained with modest efficiency by direct condensation of 16 with sodium salts of adenine, cytosine, uracil and thymine. Although a small quantity of the N 3 -isomer (less than 6%) of the adenine base was present, they were readily differentiated [UV(MeOH) λ max 279 nm].
17 Also, O 2 -isomers of pyrimidine bases such as 2-O-cyt, 2-O-ura, 2-O-thy are readily differentiated by the UV data. 18 Finally, global deprotection of intermediates 17-20 with TBAF efficiently produced the targets 4'-methyl-2'-spirocyclopropylnucleosides 21-24.
The synthesized nucleoside analogues mentioned above were assayed for their ability to inhibit HCV RNA replication in a subgenomic replicon Huh7 cell line. 19 This system is composed of a human hepatocarcinoma cell line supporting HCV replication. These cells contain an HCV subgenomic replicon RNA encoding a luciferase reporter gene as a marker. The antiviral potency of these analogues against the HCV replicon is expressed as EC 50 , which was quantified by a luciferase assay after a two-day incubation period with the compounds. To confirm the anti-HCV potency of compounds, subgenomic replicon RNA levels were quantified by real-time RT-PCR analysis. In addition, the associated cytotoxicity was evaluated in a tetrazolium (XTT)-based assay. As shown in Table 1 , the cytosine nucleoside analogue 22 showed significant anti-HCV activity. However, nucleoside analogues 23 and 24 did not show anti-HCV activity or cytotoxicity at concentrations of up to 50 μM.
In summary, based on the potent anti-HCV activity of 4'-branched nucleoside and 2'-spirocyclopropyl nucleoside analogue, we have designed and successfully synthesized novel 4'-methyl-2'-spirocarbocyclic nucleoside analogues starting from acetol. 2'-Spiroribonucleoside analogue 7 3 and 4'-azidoribonucleoside analogue 9 4 were found to inhibit HCV with an EC 50 = 7.3 μM and 1.28 μM, respectively. Taking these data into account, the proposed 4'-pocket in the active site of the RNA polymerase encoded by HCV is sensitive to electronic changes in the 4'-substituent, especially when such changes involve increasing the van der Waals radius or changing the projection angle of the 4'-substituent into the pocket.
Experimental Section
Melting points were determined on a Mel-temp II laboratory device and are uncorrected. NMR spectra were recorded on a JEOL 300 Fourier transform spectrometer (JEOL, Tokyo, Japan); chemical shifts are reported in parts per million (δ) and signals are reported as s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet) and dd (doublet of doublets). UV spectra were obtained on a Beckman DU-7 spectrophotometer (Beckman, South Pasadena, CA, USA). The elemental analyses were performed using a PerkinElmer 2400 analyzer (Perkin-Elmer, Norwalk, CT, USA). (rel)-(3R and 3S,5S)-5-(t-Butyldimethylsilanyloxymethyl)-5,6-dimethyl-hepta-1,6-dien-3-ol (6): To a solution of 5 (2.5 g, 9.75 mmol) in dry THF (25 mL) was slowly added vinylMgBr (11.7 mL, 1.0 M solution in THF) at −78 o C. After 5 h, saturated NH 4 Cl solution (12 mL) and water (70 mL) were added sequentially, and the reaction mixture was slowly warmed to rt. The mixture was extracted with EtOAc (70 mL) two times. The combined organic layer was dried over MgSO 4 , filtered, and evaporated. The residue was purified by silica gel column chromatography (EtOAc/ hexane, 1:12) to give 6 (2.02 g, 73%) as colorless oil: (rel)-(1R and 1S,4S)-4-(t-Butyldimethylsilyloxymethyl)-3,4-dimethyl-cyclopent-2-enol (7): To a solution of 6 (1.22 g, 4.30 mmol) in dry benzene (10 mL) was added 2 nd generation Grubbs catalyst (63 mg 0.075 mmol). The reaction mixture was refluxed overnight and cooled to room temperature. The mixture was concentrated in vacuo, and the residue was purified by silica gel column chromatography (EtOAc/ hexane, 1:10) to give cyclopentenol 7 (860 mg, 78%) as a diastereomeric mixture. (±)-4-(t-Butyldimethylsilanyloxymethyl)-3,4-dimethylcyclopent-2-enone (8): A mixture of allylic alcohol 7 (1.37 g, 5.34 mmol) and manganese (IV) dioxide (1.28 g, 14.8 mmol) in CCl 4 (20 mL) was stirred at 65 o C. Additional manganese (IV) dioxide (214 mg, 2.47 mmol) was added each hour and the progress of the reaction was monitored by TLC (EtOAc/ hexane, 1:30). The resultant mixture was filtered through a pad of Celite and washed with ethyl acetate. The filtrate and washes were concentrated in vacuo to give a residue that was purified by silica gel column chromatography (EtOAc/ hexane, 1:30) to give α,β-unsaturated ketone derivative 8 (937 mg, 69%) as a colorless oil. (±)-6-(t-Butyldimethylsilanyloxymethyl)-6-methyl-7-methylene-spiro [2.4] heptan-4-one (9); and (±)-7-(tbutyldimethylsilanyloxymethyl)-6,7-dimethyl-spiro[2.4]hept-5-en-4-one (9'): A solution of bicyclic enone 8 (346 mg, 1.36 mmol) in t-butyl alcohol (4.0 mL) was added to a stirred mixture of potassium t-butoxide (615 mg, 5.5 mmol) in t-butyl alcohol (4.0 mL). After the mixture was stirred at room temperature for 20 min, potassium iodide (455 mg, 2.75 mmol) and (2-chloroethyl)dimethylsulfonium iodide (640 mg, 2.55 mmol) were added in portions under a stream of nitrogen. The mixture was stirred at room temperature for 1.5 h, diluted with saturated NH 4 Cl solution (20 mL), and extracted with ether (3 × 30 mL). The combined organic layer was washed with brine, dried under anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography (EtOAc/hexane, 1:25) on silica gel to give ketones 9 (110 mg, 29%) and 9' (129 mg, 34%) as colorless oil. Spectral date for 9: (11) : NaH (60% in mineral oil, 1.66 g, 41.6 mmol) was added portion-wise to a cooled (0 o C) solution of 10a (9.79 g, 34.67 mmol) in DMF (100 mL) and p-methoxybenzyl chloride (5.17 mL, 38.13 mmol) in anhydrous DMF (50 mL). The reaction mixture was stirred at rt overnight. The solvent was quenched with H 2 O, removed under reduced pressure and extracted with EtOAc (2 × 100 mL). The combined organic layer was washed with brine, dried over anhydrous MgSO 4 , and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (EtOAc/hexane, 1:10) to give 11 (10.88 g, 78%) as a colorless oil. (
(rel)-(5S,7S)-6-t-Butyl-[7-(4-methoxybenzyloxy)-5-methyl-4-methylenespiro[2.4]hept-5-ylmethoxy]-dimethylsilane

rel)-(5S,7S)-5-(t-Butyldimethylsilanyloxymethyl)-7-(4-methoxybenzyloxy)-5-methyl-spiro[2.4]heptan-4-one (12):
A solution of compound 11 (3.87 g, 9.62 mmol) in anhydrous CH 2 Cl 2 (50 mL) was cooled to −78 o C, and ozone gas was then bubbled into the reaction mixture until a blue color persisted for 10 minutes. The reaction mixture was degassed with nitrogen, and dimethyl sulfide (2.97 mL, 40.41 mmol) was slowly added at −78 o C. The mixture was stirred for 1 h at −78 o C under argon gas and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (EtOAc/hexane, 1:12) to give compound 12 (2.96 g, 76%) as a colorless oil. Compounds 13a and 13b were synthesized from 12 using a similar procedure as described for 10a and 10b. Spectral data for 13a: yield 59%; (rel)-(4S,6S,7S)-7-(t-Butyldimethylsilanyloxy)-6-(t-butyldimethylsilanyloxymethyl)-6-methyl-spiro[2.4]heptan-4-ol (15): To a solution of compound 14 (1.41 g, 2.71 mmol) in CH 2 Cl 2 /H 2 O mixture (12 mL, 20:1 v/v) was added DDQ (672 mg, 3.69 mmol) and the mixture was stirred for 4 h at room temperature. Saturated NaHCO 3 (3 mL) was added to quench the reaction and further diluted with water (50 mL). The organic layer was separated, washed with brine, dried over anhydrous MgSO 4 , and filtered. The filtrate was concentrated under reduced pressure and the residue was purified by silica gel column chromatography (EtOAc/ hexane, 1:15) to give compound 15 (879 mg, 81%) as a colorless oil. The reaction mixture was stirred for 4 h, allowed to warm to rt, quenched with saturated NaHCO 3 solution (1.0 mL), and further diluted with water (80 mL). The mixture was extracted with Et 2 O (3 × 80 mL). The combined organic phases were dried and concentrated. The residue was purified by silica gel column chromatography (EtOAc/hexane, 1:15) to give compound 16 (879 mg, 75%) as a colorless oil. 32 (s, 3H) 
